Low effectiveness of DNA vaccination against HER-2/neu in ageing

Vaccine

Volumn 21, Issue 9-10, 2003, Pages 843-848

  Provinciali, Mauro ^a   Smorlesi, Arianna ^a   Donnini, Alessia ^a   Bartozzi, Beatrice ^a   Amici, Augusto ^b  

^a INRCA   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Ageing; DNA vaccination; HER 2 neu

Indexed keywords

CYTOMEGALOVIRUS VACCINE; DNA VACCINE; PROTEIN ANTIBODY; PROTEIN P185;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; CANCER PREVENTION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; IMMUNITY; IMMUNIZATION; LUNG CARCINOMA; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; ONCOGENE NEU; PLASMID; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; VACCINATION;

AGING; ANIMALS; CANCER VACCINES; GENES, ERBB-2; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PLASMIDS; TRANSPLANTATION, ISOGENEIC; TUMOR CELLS, CULTURED; VACCINES, DNA;

EID: 0037435886     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00530-3     Document Type: Conference Paper

References (18)

1. Finn O.J., Forni G. Prophylactic cancer vaccines. Curr. Opin. Immunol. 14(2):2002;172-177.
2. Quaglino E., Rovero S., Cavallo F.et al. Immunological prevention of spontaneous tumours: a new prospect? Immunol. Lett. 80(2):2002;75-79.
3. Nanni P., Nicoletti G., De Giovanni C.et al. Combined allogeneic tumour cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194(9):2001;1195-1205.
4. Di Carlo E., Rovero S., Boggio K.et al. Inhibition of mammary carcinogenesis by systemic interleukin-12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Clin Cancer Res. 7(Suppl 3):2001;830s-837s.
5. Cavallo F., Signorelli P., Giovarelli M.et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89(14):1997;1049-1058.
6. Colombo M.P., Forni G. Cytokine gene transfer in tumour inhibition and tumour therapy: where are we now? Immunol Today. 15(2):1994;48-51.
7. Fabris N., Mocchegiani E., Provinciali M. Plasticity of neuro-endocrine-thymus interactions during ageing. Exp. Gerontol. 32:1997;415-430.
8. Pawelec G., Solana R. Immunosenescence. Immunol Today. 18:1997;514-516.
9. George A.J.T., Ritter M.A. Thymic involution with ageing: obsolescence or good housekeeping? Immunol. Today. 17:1996;267-272.
10. Provinciali M., Argentati K., Tibaldi A. Efficacy of cancer gene therapy in ageing: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumour specific immune memory in old mice. Gene Ther. 7:2000;624-632.
11. Slamon D.J., Godolphin W., Jones L.A.et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244(4905):1989;707-712.
12. Berchuck A., Kamel A., Whitaker R.et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50(13):1990;4087-4091.
13. Amici A., Smorlesi A., Noce G.et al. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumours in HER-2/neu transgenic mice. Gene Ther. 7(8):2000;703-706.
14. Rovero S., Amici A., Carlo E.D.et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165(9):2000;5133-5142.
15. Arase H., Arase N., Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 181:1995;1235-1238.
16. Bryant J., Day R., Whiteside T., Herberman R.B. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J. Immunol. Methods. 146:1992;91-96.
17. Giovarelli M., Musiani P., Modesti A.et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J. Immunol. 155(6):1995;3112-3123.
18. Nagata Y., Furugen H., Ikeda N.et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/2 neu can induce CTL and tumour suppression in syngeneic hosts. J. Immunol. 159:1997;1336-1402.